BACKGROUND: In antiretroviral therapy (ART) programs, decreasing loss to follow up (LTFU) is a major priority. METHODS: We conducted a prospective study in Abidjan. Adults who started ART between June 2005 and May 2008 and were still in care 6 months later had monthly visits, biannual CD4 counts, computerized data collection and home visits (routine follow-up). A subset of patients also had biannual plasma HIV-1 RNA measurements, with a physician and a research assistant hired to pay particular attention to their visits (enhanced follow-up). We analyzed the association between 18-month outcomes and pre-ART characteristics, medication possession ratio (MPR) and type of follow-up. Patients were LTFU if their last visit was before month-18 and they had not returned to care by month-24. RESULTS: 2,074 patients started ART, of whom 1,636 (79%) were still in care at month-6. The routine (n = 999) and enhanced (n = 637) groups had similar baseline characteristics. From month-6 to month-18, they had similar death rates (routine 3.6%, enhanced 3.9%, P = 0.74), but the enhanced group had significantly less LTFU (routine 11.3%, enhanced 5.8%, P < 0.001). In multivariate analysis, the risk of LTFU from month-6 to month-18 was 46% lower with enhanced follow-up, 56% higher in patients living outside the centre area, and 4.0 fold higher in patients with a low MPR (<80%) between ART initiation and month-6. CONCLUSIONS: In patients still in care at 6 months, a low MPR in the first 6 months was strongly associated with further LTFU. Simple follow-up enhancement halved the LTFU rate in the following year.
BACKGROUND: In antiretroviral therapy (ART) programs, decreasing loss to follow up (LTFU) is a major priority. METHODS: We conducted a prospective study in Abidjan. Adults who started ART between June 2005 and May 2008 and were still in care 6 months later had monthly visits, biannual CD4 counts, computerized data collection and home visits (routine follow-up). A subset of patients also had biannual plasma HIV-1 RNA measurements, with a physician and a research assistant hired to pay particular attention to their visits (enhanced follow-up). We analyzed the association between 18-month outcomes and pre-ART characteristics, medication possession ratio (MPR) and type of follow-up. Patients were LTFU if their last visit was before month-18 and they had not returned to care by month-24. RESULTS: 2,074 patients started ART, of whom 1,636 (79%) were still in care at month-6. The routine (n = 999) and enhanced (n = 637) groups had similar baseline characteristics. From month-6 to month-18, they had similar death rates (routine 3.6%, enhanced 3.9%, P = 0.74), but the enhanced group had significantly less LTFU (routine 11.3%, enhanced 5.8%, P < 0.001). In multivariate analysis, the risk of LTFU from month-6 to month-18 was 46% lower with enhanced follow-up, 56% higher in patients living outside the centre area, and 4.0 fold higher in patients with a low MPR (<80%) between ART initiation and month-6. CONCLUSIONS: In patients still in care at 6 months, a low MPR in the first 6 months was strongly associated with further LTFU. Simple follow-up enhancement halved the LTFU rate in the following year.
Authors: Portia C Mutevedzi; Richard J Lessells; Tom Heller; Till Bärnighausen; Graham S Cooke; Marie-Louise Newell Journal: Bull World Health Organ Date: 2010-05-10 Impact factor: 9.408
Authors: Vincent Ochieng-Ooko; Daniel Ochieng; John E Sidle; Margaret Holdsworth; Kara Wools-Kaloustian; Abraham M Siika; Constantin T Yiannoutsos; Michael Owiti; Sylvester Kimaiyo; Paula Braitstein Journal: Bull World Health Organ Date: 2010-04-16 Impact factor: 9.408
Authors: Elvin H Geng; David V Glidden; Nneka Emenyonu; Nicolas Musinguzi; Mwebwesa Bosco Bwana; Torsten B Neilands; Winnie Muyindike; Constantin T Yiannoutsos; Steven G Deeks; David R Bangsberg; Jeffrey N Martin Journal: Trop Med Int Health Date: 2010-06 Impact factor: 2.622
Authors: Didier K Ekouevi; Eric Balestre; Franck-Olivier Ba-Gomis; Serge Paul Eholie; Moussa Maiga; Clarisse Amani-Bosse; Albert Minga; Eugène Messou; Papa Salif Sow; Charlotte Lewden; Hamar Allassane Traoré; Emmanuel Bissagnene; François Dabis Journal: Trop Med Int Health Date: 2010-06 Impact factor: 2.622
Authors: Andrew Boulle; Gilles Van Cutsem; Katherine Hilderbrand; Carol Cragg; Musaed Abrahams; Shaheed Mathee; Nathan Ford; Louise Knight; Meg Osler; Jonny Myers; Eric Goemaere; David Coetzee; Gary Maartens Journal: AIDS Date: 2010-02-20 Impact factor: 4.177
Authors: Martin W G Brinkhof; François Dabis; Landon Myer; David R Bangsberg; Andrew Boulle; Denis Nash; Mauro Schechter; Christian Laurent; Olivia Keiser; Margaret May; Eduardo Sprinz; Matthias Egger; Xavier Anglaret Journal: Bull World Health Organ Date: 2008-07 Impact factor: 9.408
Authors: Eugène Messou; Xavier Anglaret; Julien Duvignac; Eric Konan-N'dri; Eric Komena; Joachim Gnokoro; Sophie Karcher; Anthony Tanoh; Thérèse N'dri-Yoman; Catherine Seyler Journal: AIDS Date: 2010-01-02 Impact factor: 4.177
Authors: April D Kimmel; Stephen C Resch; Xavier Anglaret; Norman Daniels; Sue J Goldie; Christine Danel; Angela Y Wong; Kenneth A Freedberg; Milton C Weinstein Journal: Cost Eff Resour Alloc Date: 2012-09-19
Authors: Andrew F Auld; Kunomboa A Ekra; Ray W Shiraishi; Moise Z Tuho; Joseph S Kouakou; Fayama Mohamed; Virginie Ettiègne-Traoré; Jennifer Sabatier; Joseph Essombo; Georgette Adjorlolo-Johnson; Richard Marlink; Tedd V Ellerbrock Journal: PLoS One Date: 2014-05-27 Impact factor: 3.240
Authors: Emily P Hyle; Ilesh V Jani; Jonathan Lehe; Amanda E Su; Robin Wood; Jorge Quevedo; Elena Losina; Ingrid V Bassett; Pamela P Pei; A David Paltiel; Stephen Resch; Kenneth A Freedberg; Trevor Peter; Rochelle P Walensky Journal: PLoS Med Date: 2014-09-16 Impact factor: 11.069
Authors: Amy Zheng; Nagalingeswaran Kumarasamy; Mingshu Huang; A David Paltiel; Kenneth H Mayer; Bharat B Rewari; Rochelle P Walensky; Kenneth A Freedberg Journal: J Int AIDS Soc Date: 2018-03 Impact factor: 5.396
Authors: Anne M Neilan; Jennifer Cohn; Emma Sacks; Aditya R Gandhi; Patricia Fassinou; Rochelle P Walensky; Marc N Kouadio; Kenneth A Freedberg; Andrea L Ciaranello Journal: Open Forum Infect Dis Date: 2021-05-13 Impact factor: 3.835